Recent research has indicated that GLP-1 medications, commonly used for weight management in individuals with obesity or type 2 diabetes, may also have a positive impact on testosterone levels in men. The study, presented by Dr. Shellsea Portillo Canales at the Endocrine Society’s annual meeting, analyzed the health records of 110 males, primarily in their mid-50s, who were undergoing treatment with GLP-1 receptor agonists such as semaglutide and tirzepatide over 18 months.
The findings revealed that the average participant lost approximately 26 pounds, leading to a significant increase in both total and free testosterone levels. At the study's outset, just over half of the participants had testosterone levels below the recognized threshold of 300 ng/dL. After treatment, this proportion dropped to 23%, with average total testosterone levels rising from 322 ng/dL to 380 ng/dL.
Obesity and type 2 diabetes are established risk factors for low testosterone, and prior studies have shown that weight loss can enhance hormone levels. While GLP-1 medications are not directly stimulating testosterone production, the associated weight loss appears to be the key factor in improving testosterone levels. Researchers emphasize the importance of lifestyle changes, including weight loss, as a first-line approach in addressing low testosterone in men, particularly those whose conditions are linked to obesity.
Experts in the field are optimistic about these preliminary findings, which suggest that GLP-1 medications may also contribute positively to sexual health. As research continues, the potential for these medications to provide broader health benefits alongside weight loss is gaining recognition.